mercredi 30 septembre 2026
RechercherExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 16, 2026

Uterine Fibroid Market Size to Reach USD 9.43 Billion by 2033 with 7.63% CAGR – SNS Insider

View original at globenewswire.com
Uterine Fibroid Market Size to Reach USD 9.43 Billion by 2033 with 7.63% CAGR – SNS Insider Austin, United States, Feb…
Opening lines of the source · short snapshot — read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • MRI-Guided Focused Ultrasound (MRgFUS) is expected to grow at the fastest CAGR of 8.83% from 2026 to 2033

    80% confidence
  • Laparoscopic Surgery dominated with 36.58% in 2025 due to its widespread adoption, proven safety, and effectiveness

    80% confidence
  • Hospitals & Clinics dominated with 47.49% market share in 2025

    80% confidence
  • Intramural Fibroids is expected to grow at the fastest CAGR of 8.20% from 2026 to 2033

    80% confidence
  • Surgical Procedures dominated with 38.45% market share in 2025

    80% confidence
  • Healthcare expenditures in developing regions have grown by an approximate 45% over the last decade

    80% confidence
  • African American women have a high risk of uterine fibroids, occurring at a younger age with severe symptoms compared to other ethnicities

    80% confidence
  • African American women have a high risk of uterine fibroids, occurring at a younger age with severe symptoms compared to other ethnicities

    80% confidence
  • The Uterine Fibroid Market size was valued at USD 5.26 Billion in 2025 and is projected to reach USD 9.43 Billion by 2033 and grow at a CAGR of 7.63% over the forecast period 2026-2033

    80% confidence
  • Laparoscopic Surgery dominated with 36.58% in 2025 due to its widespread adoption, proven safety, and effectiveness

    80% confidence
  • The Uterine Fibroid Market size was valued at USD 5.26 Billion in 2025 and is projected to reach USD 9.43 Billion by 2033

    80% confidence
  • Uterine fibroids occur in approximately 70 to 80% of women by the age of 50

    80% confidence
  • The uterine fibroid market will grow at a CAGR of 7.63% over the forecast period 2026-2033

    80% confidence
  • Uterine fibroids occur in approximately 70 to 80% of women by the age of 50

    80% confidence
  • Intramural Fibroids is expected to grow at the fastest CAGR of 8.20% from 2026 to 2033

    80% confidence
  • Asia Pacific is expected to grow at the fastest CAGR from 2026–2033 in the Uterine Fibroid Market

    80% confidence
  • The Uterine Fibroid Market will grow at a CAGR of 7.63% over the forecast period 2026-2033

    80% confidence
  • Minimally Invasive Procedures is expected to grow at the fastest CAGR of 8.63% from 2026 to 2033

    80% confidence
  • Minimally invasive techniques, including laparoscopic myomectomy, uterine artery embolization, and MRI-guided focused ultrasound, have seen adoption rates rise by more than 60% in the past five years

    80% confidence
  • The Uterine Fibroid Market size was valued at USD 5.26 Billion in 2025 and is projected to reach USD 9.43 Billion by 2033 and grow at a CAGR of 7.63% over the forecast period 2026-2033

    80% confidence
  • Uterine fibroids occur in approximately 70 to 80% of women by the age of 50

    80% confidence
  • Minimally Invasive Procedures is expected to grow at the fastest CAGR of 8.63% from 2026 to 2033

    80% confidence
  • Uterine fibroids are common among women between the ages of 30 to 40 years, with varying rates among different ethnic groups

    80% confidence
  • Healthcare expenditures in developing regions have grown by an approximate 45% over the last decade

    80% confidence
  • Asia Pacific is expected to grow at the fastest CAGR from 2026-2033 in the Uterine Fibroid Market

    80% confidence
  • Surgical Procedures dominated with 38.45% market share in 2025

    80% confidence
  • Ambulatory Surgical Centers is expected to grow at the fastest CAGR of 8.43% from 2026 to 2033

    80% confidence
  • Uterine fibroids occur in approximately 70 to 80% of women by the age of 50

    80% confidence
  • MRI-Guided Focused Ultrasound (MRgFUS) is expected to grow at the fastest CAGR of 8.83% from 2026 to 2033

    80% confidence
  • Minimally Invasive Procedures expected to grow at the fastest CAGR of 8.63% from 2026 to 2033

    80% confidence
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
The Agentic Takeover of the CFO's Office
Enterprise finance software vendors—BlackLine, OneStream, Numero AI, and Oracle—are racing to embed autonomous AI agents into core financial operations (close, consolidation, reporting), backed by consolidation M&A (Numero-Royu, BlackLine-WiseLayer), fresh leadership hires, and survey data showing nearly a quarter of CFOs plan to boost AI spending over 50%. Adoption momentum is strong even as at least one bellwether (Oracle) sees its stock lag year-to-date, suggesting the market hasn't yet fully priced in the shift from AI-as-feature to AI-as-agent in finance.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Morgan Stanley & Co. LLC
Two significantly different EPS values (10.21 vs 2.68 USD_per_share) are reported for Morgan Stanley on the same observation date (2025-12-31). Fact A specifies FY 2025, while Fact B's 'N/A' fiscal period is ambiguous. If both represent FY 2025 annual EPS, these values directly conflict. The magnitude of the difference (3.8x) is too large to attribute to rounding or minor calculation variations. The missing fiscal period in Fact B raises data quality concerns, but same-date observation + same attribute should reference the same period.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,984
faits reliés à leur source — et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,984 faits vérifiés avec la source5,315 documents sources archivés
Interrogez ces données → isubstrate.com